Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097147 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo
A Phase 1 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 202
- Enrollment target
NCT02097147: Completed Phase 1 study, sponsored by Forest Laboratories.
NCT02097147 is a Phase 1 study that has completed, run by Forest Laboratories. The registered enrollment target is 202 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (237% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02097147, a Phase 1 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 202 participants
- Enrollment target
Study Summary
To compare the effects of vilazodone, paroxetine and placebo on sexual function in sexually active healthy adults.
Primary Outcome
The CSFQ is a subject-rated scale designed to measure changes in sexual function and is a structured, self-report, 14-item questionnaire, that measures sexual functioning as a total score (all 14 items), and on the subscales of pleasure, desire/frequency, desire/interest, arousal, and orgasm, rated on a 5 point scale, with each item rated from 1 to 5, and a total score range of 14 to 70. Lower scores are associated with worsened sexual functioning.
Interventions
- DRUG Placebo
- DRUG Vilazodone 20 mg
- DRUG Vilazodone 40 mg
- DRUG Paroxetine 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
What the finished NCT02097147 record still lists
NCT02097147 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (237% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02097147 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02097147 about?
NCT02097147 is a clinical study titled "Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo". To compare the effects of vilazodone, paroxetine and placebo on sexual function in sexually active healthy adults.
What is the current status of trial NCT02097147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 202 participants. The study started on 2014-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02097147?
The interventions under investigation include: Placebo (DRUG), Vilazodone 20 mg (DRUG), Vilazodone 40 mg (DRUG), Paroxetine 20 mg (DRUG).
Who is sponsoring clinical trial NCT02097147?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02097147's enrollment target sits among peer trials
202 258th of 2000 higher than 1,743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia